Monday, April 6, 2020, 12:00 AM - Tuesday, April 6, 2021, 11:59 PM

Early pacing devices with transvenous leads offered single-chamber, fixed-rate ventricular pacing for life-threatening conduction system disease. Tremendous advances in generator and lead technology and the results of clinical trials over the past 50 years have expanded the indications for the devices and the therapies they provide. As a result, more individuals are receiving device therapy; approximately 200,000 pacemakers are implanted every year in the United States.

Conventional pacing systems with transvenous leads have a low overall complication rate, but issues can develop with the leads and pacemaker pocket. These include pocket infections, complications during lead insertion (e.g., pneumothorax), lead fracture and malfunction, venous obstruction, and tricuspid valve regurgitation. Leadless pacemakers avoid these potential complications by being inserted directly into the right ventricle, without a lead and without the need for a pacemaker pocket. Leadless pacing has been proven to be a safe and reliable technology and will play an expanding role in bradycardia therapy.

Sponsors
Jointly Provided by Rutgers Biomedical and Health Sciences and RWJBarnabas Health

         

Faculty

Marc Roelke, MD
Director of Electrophysiology, Newark Beth Israel Medical Center, Newark, NJ and Saint Barnabas Medical Center, Livingston, NJ

Peer Review Statement
In order to help ensure content objectivity, independence, and fair balance, and to ensure that the content is aligned with the interest of the public, RBHS has resolved all potential and real conflicts of interest through content review by a non-conflicted, qualified reviewer. This activity was peer-reviewed for relevance, accuracy of content, and balance of presentation by:

Gary J. Rogal, MD, FACC
Medical Director for RWJBarnabas Health Cardiac Services, Livingston, NJ

Field Test Statement
This activity was pilot-tested for time required for participation by Aakash Garg, MD, Zain Khakwani, MD and Snehitha Vijaykumar, MD.

1. Discuss the history and clinical impact of modern day cardiac pacing
2. Compare the complications of transvenous pacemakers to leadless pacemakers based on the latest evidence
3. Review the physical features and the implementation procedure of the leadless cardiac pacing system
4. Summarize the advantages and disadvantages of leadless cardiac pacing

In order to access the activity, please click on the "Register" tab and complete your registration or enter your log-in information. Then click on the "Online Content & Tests" tab and select "Media" to view the activity.

How to Receive CE Credit: Participants should review the activity in its entirety and complete the post-test by clicking on the "Online Content & Tests" tab and selecting "Test." Upon achieving a passing score of 66% or more on the post-test, click on "Complete Evaluation" and submit your evaluation. Participants will then be able to download their CE certificate. The CE certificate will also be emailed.

In support of improving patient care, this activity has been planned and implemented by Rutgers Biomedical and Health Sciences and RWJBarnabas Health. Rutgers Biomedical and Health Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians: Rutgers Biomedical and Health Sciences designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Advanced Practice Nurses, Nurses and Physician Assistants may participate in this educational activity and earn a letter of attendance as AANP, ANCC and AAPA accept AMA PRA Category 1 Credits™ through their reciprocity agreements.

ABIM MOC Points

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Estimated time to complete this activity as designed is 0.25 hours.

Disclosure: In accordance with the disclosure policies of Rutgers and to conform with Joint Accreditation requirements and FDA guidelines, individuals in a position to control the content of this education activity are required to disclose to the activity participants: the existence of any relevant financial relationship with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients, with the exemption of non-profit or government organizations and non-health care related companies, within the past 12 months; and the identification of a commercial product/device that is unlabeled for use or an investigational use of a product/device that is not yet approved.

Faculty
Marc Roelke, MD, has disclosed the following relevant financial relationships: Grant/Research Support and Consultant: Abbott, Boston Scientific, Medtronic

Peer Reviewer
Gary J. Rogal, MD has no relevant financial relationships to disclose.

Field Testers
Drs. Garg, Khakwani and Vijaykumar have no relevant financial relationships to disclose.

Planners
RBHS Center for Continuing Outreach and Education
Patrick Dwyer, Director, Continuing Medical Education, has no relevant financial relationships to disclose.

RWJBarnabas Health
Lauren Burke, Vice President, Cardiac Quality and Performance Improvement, and Lisa Clarke, Project Manager, have no relevant financial relationships to disclose.

Off-Label/Investigational Use Disclosure: Faculty are required to disclose discussion of off-label/investigational uses of commercial products/devices in their presentation. These disclosures will be made to the audience at the time of the activity.

Content Disclaimer: The views expressed in this activity are those of the faculty. It should not be inferred or assumed that they are expressing the views of any manufacturer of pharmaceuticals or devices, Rutgers University or RWJBarnabas Health.

It should be noted that the recommendations made herein with regard to the use of therapeutic agents, varying disease states, and assessments of risk, are based upon a combination of clinical trials, current guidelines, and the clinical practice experience of the participating presenters. The drug selection and dosage information presented in this activity are believed to be accurate. However, participants are urged to consult all available data on products or procedures before using them in clinical practice.

Copyright © 2020. Rutgers Biomedical and Health Sciences and RWJBarnabas Health. All rights reserved including translation into other languages. No part of these activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording or any information storage and retrieval systems, without written permission from the Rutgers.

Questions: Please direct content, CE-related or technical questions or concerns to Rutgers Center for Continuing and Outreach Education (CCOE) by email at ccoe@rbhs.rutgers.edu.

To review CCOE's privacy policy, please click here.

AMA PRA Category 1 Credits™ (0.25 hours), Non-Physician Attendance (0.25 hours), ABIM MOC Part 2 (0.25 hours)